WW buys Sequence for telehealth integration

This deal showed that WW had stopped treating digital as a support feature and started treating it as the core battleground. Sequence gave WW a working telehealth engine for obesity care, with clinicians, insurance navigation, and prescription management already in place, so WW could pair its behavior program with medication access instead of asking members to go elsewhere for GLP-1s.

• Sequence was not a small experiment. At acquisition announcement in March 2023, it was serving about 24,000 members and running at roughly $25M in annual revenue, which meant WW was buying immediate clinical infrastructure, not just software.
  1 globenewswire
• The strategic fit was simple. WW already had brand, behavior coaching, and a large member base. Sequence added the doctor visit, prescription workflow, and prior authorization support that matter when weight loss shifts from tracking points to getting and staying on GLP-1 medication.
  1 globenewswire 2 globenewswire 4 sec
• That moved WW closer to Noom's newer shape and to telehealth players like Ro and Hims & Hers. The market was no longer just about habit coaching apps. It was becoming a higher value bundle of coaching, medication access, refill management, and long term retention.
  3 sacra 4 sec

The next phase is a tighter merge of behavior change and medical care into one recurring subscription. As GLP-1 use expands, weight loss companies that can own the full loop, from onboarding to prescription to daily support inside one app, will take share from legacy programs built around meetings first.